MetaCap

Neumora Therapeutics (NMRA) vs Tenaya Therapeutics (TNYA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tenaya Therapeutics (TNYA) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 76.7% versus a loss of 85.7%. Tenaya Therapeutics is the larger company by market cap ($65.3 million vs $63.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NMRA-85.67%TNYA-76.70%
+61%-16%-93%
Nov 21, 20251 yearNov 20, 2026
NMRA-97.95%TNYA-91.07%
+118%+5%-108%
Sep 11, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NMRA versus TNYA key metrics
MetricNMRATNYA
Share price$0.3339$0.2866
Market cap$63.01M$65.32M
1-day change-3.78%-3.99%
YTD return-81.35%-59.75%
1-year return-85.67%-76.70%
5-year return—-98.50%
EPS (TTM)$-1.06$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-236.93M$-90.60M
52-week high$3.65$1.46
52-week low$0.301$0.28
Distance from 52-week high-90.85%-80.37%
Analyst consensusbuynone
Avg. price target upside+1696.95%+1016.54%
Average volume1.69M2.96M
Shares outstanding188.69M227.93M
Employees6370
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Neumora Therapeutics

NMRA stock →

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees

About Tenaya Therapeutics

TNYA stock →

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees

NMRA vs TNYA FAQ

Which is bigger, Neumora Therapeutics or Tenaya Therapeutics?

Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $65.32M compared with $63.01M for Neumora Therapeutics (NMRA).

Which stock has performed better over the past year, NMRA or TNYA?

TNYA returned -76.70% over the past 12 months, compared with -85.67% for NMRA (price return, excluding dividends). Past performance does not predict future results.

Are Neumora Therapeutics and Tenaya Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons